Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | GRM4 | Q14833 | 16/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591083 | 0.83 | GRM4 (0.59) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL2593847 | 0.80 | GRM4 (0.58) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL2593919 | 0.79 | RAB9A (0.60) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL30522196 | 0.79 | GRM4 (0.56) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL12248914 | 0.77 | ALDH1A1 (0.66) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL28480808 | 0.76 | TLR7 (0.55) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL2385907 | 0.75 | NPC1 (1.00) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL2594378 | 0.75 | NPC1 (0.69) | NPC1RAB9APKMGRM4MAPT | |
| SCHEMBL21511019 | 0.75 | SMN1; SMN2 (0.66) | NPC1RAB9APKMMAPTOPRK1 | |
| SCHEMBL30263346 | 0.75 | PDE5A (0.64) | NPC1RAB9APKMMAPTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192603-B2 | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2568809-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143466-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | NPC1 3626/4885RAB9A 2120/4885PKM 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.